Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
British Journal of Haematology
|
January 31, 2013
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
Girija Dasmahapatra, Hiral Patel, Paul Dent, et al.
Leukemia Research
|
February 2, 2010
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
Tri K Nguyen, Nicholas Jordan, Jonathan Friedberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2014
PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo
Mohamed Rahmani, Mandy Mayo Aust, Elisa C Benson, et al.
Blood
|
March 18, 2010
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
Girija Dasmahapatra, Dmitry Lembersky, Lora Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group
Steven H Bernstein, Joseph M Unger, Michael Leblanc, et al.
Cancer Biology & Therapy
|
March 10, 2009
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress
Girija Dasmahapatra, Dmitry Lembersky, Mohamed Rahmani, et al.
Leukemia & Lymphoma
|
May 9, 2008
Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept
Jonathan Friedberg, Eric Jacobsen, Donna Neuberg, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 13, 2010
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel
Bruce D Cheson, Clemens-Martin Wendtner, Angelika Pieper, et al.
Leukemia Research
|
June 24, 2008
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML
Alison R Walker, Rami S Komrokji, Jainulabdeen Ifthikharuddin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2002
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger
Andrea K Ng, M Patricia Bernardo, Edie Weller, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
British Journal of Haematology
|
January 31, 2013
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
Girija Dasmahapatra, Hiral Patel, Paul Dent, et al.
Leukemia Research
|
February 2, 2010
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
Tri K Nguyen, Nicholas Jordan, Jonathan Friedberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2014
PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo
Mohamed Rahmani, Mandy Mayo Aust, Elisa C Benson, et al.
Blood
|
March 18, 2010
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
Girija Dasmahapatra, Dmitry Lembersky, Lora Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group
Steven H Bernstein, Joseph M Unger, Michael Leblanc, et al.
Cancer Biology & Therapy
|
March 10, 2009
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress
Girija Dasmahapatra, Dmitry Lembersky, Mohamed Rahmani, et al.
Leukemia & Lymphoma
|
May 9, 2008
Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept
Jonathan Friedberg, Eric Jacobsen, Donna Neuberg, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 13, 2010
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel
Bruce D Cheson, Clemens-Martin Wendtner, Angelika Pieper, et al.
Leukemia Research
|
June 24, 2008
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML
Alison R Walker, Rami S Komrokji, Jainulabdeen Ifthikharuddin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2002
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger
Andrea K Ng, M Patricia Bernardo, Edie Weller, et al.
Page
of 3